REGISTER
AAIC 2025 | Secrets of Gut-Brain Axis: How Age, Gender and APOE Genotype Modify Alzheime
Gut-Brain Axis Revealed: Age, Sex and APOE Genotype Alter AD Risk Through Gut Microbiota

Alzheimer’s disease (AD) ranks among the most prevalent neurodegenerative disorders. With advances in detection technologies, AD research has shifted from single-pathway models toward multi-dimensional exploration, with the gut-brain axis gaining mounting research attention.

Presented at the 2025 Alzheimer’s Association International Conference (AAIC) held in Canada from July 27 to 31, research led by Professor W.M.A.D. Binosha Fernando from Edith Cowan University, Australia, revealed measurable gut microbiota alterations emerge in the preclinical stage of AD and are closely tied to age, sex and the APOE ε4 genotype. The team analyzed preclinical cohorts to unpack how gut flora drives early AD pathogenesis.

Unresolved puzzles linking gut microbiota to early AD

The gut and brain communicate via the gut-brain axis, where intestinal microbiota exert core regulatory effects. These microbes modulate immunity and cerebral homeostasis; their metabolites including short-chain fatty acids (SCFAs) regulate inflammation, blood-brain barrier integrity and beta-amyloid (Aβ) deposition, key pathological hallmarks of AD.

Prior studies have established baseline correlations: aging reduces microbial diversity, depleting beneficial SCFA-producing bacteria while enriching pro-inflammatory clostridia strains; females tend to have lower levels of protective Lactobacillus, whereas males harbour more stable gut microbiome; APOE ε4 carriers feature fewer commensal microbes and excess pro-inflammatory taxa. However, most existing data were collected from patients with mild cognitive impairment (MCI) or diagnosed AD. Evidence describing gut flora changes among cognitively intact preclinical individuals remains scarce, motivating the present investigation.

Distinct gut microbial signatures identified in preclinical AD

The research enrolled cognitively unimpaired preclinical participants from an Australian neuroimaging database, stratified into high and low Aβ groups according to cerebrospinal fluid Aβ concentrations. Microbiome profiling via mNGS yielded key findings:

1. Species composition: 16 unique preclinical AD-associated microbial species

Twenty phyla were identified across samples, dominated by Bacteroidetes, Firmicutes and Proteobacteria, consistent across top-abundant genera and species. Sixteen differentially abundant species specific to preclinical AD were newly discovered, with most beneficial taxa enriched in the low-Aβ cohort.

2. Diversity disparities favour low-Aβ individuals

No significant between-group differences in Shannon α-diversity, yet low-Aβ subjects displayed denser microbial distribution indicating higher richness. β-diversity analysis showed partial taxonomic overlap, with more scattered microbiota in high-Aβ participants. Middle-aged cohorts had higher Firmicutes abundance than younger and elderly groups; females carried more Bacteroidetes but fewer Firmicutes, opposite to males who possessed elevated beneficial microbes.

3. APOE ε4 non-carriers harbour favourable microbial profiles

APOE ε4 non-carriers had richer beneficial gut bacteria, while carriers showed predominance of pro-inflammatory microbes. Metabolite testing revealed elevated ascorbate (linked to Aβ aggregation) yet reduced butyrate in low-Aβ subjects; men produced higher butyrate than women, and circulating ascorbate and butyrate declined progressively with age, with APOE ε4 carriers displaying unique metabolic signatures. These observations partly explain superior gut microbiome stability in males.

4. Active protective metabolic pathways within low-Aβ cohorts

Probiotics including Lactobacillus and Bifidobacterium, normally present at under 1% relative abundance, were significantly enriched in low-Aβ participants. Genes governing SCFA biosynthesis were upregulated in this group, and network analysis validated biological crosstalk between SCFAs, H6 and APP (amyloid precursor protein).

5. Neuroprotective effects of sodium butyrate validated via cellular assays

In vitro testing confirmed sodium butyrate suppresses pro-inflammatory cytokines IL-6 and IL-8, restores anti-inflammatory IL-4, upregulates antioxidant enzymes CAT and G6PD, and rescues MFN1 expression to preserve mitochondrial integrity. Multiple previously unreported microRNA expression shifts were also detected in preclinical AD samples.

Implications for personalized AD intervention

For the first time, the study confirms preclinical gut microbiome divergence driven by cerebral Aβ load, age, sex and APOE genotype: low-Aβ individuals retain richer beneficial microbes and active metabolic pathways; middle-aged populations have abundant Firmicutes; males show more stable gut flora; APOE ε4 non-carriers possess enhanced commensal reserves.

These results revise the consensus that gut dysbiosis only arises after clinical AD onset and position gut microbiota as a promising early intervention target. Personalized supplementation with Lactobacillus, Bifidobacterium or SCFA supplements could help balance intestinal flora in high-risk groups such as females and APOE ε4 carriers.

Future research directions

  • Standardized patient stratification: Combine Aβ, tau and multi-biomarker readouts to refine cohort classification beyond sole Aβ quantification.
  • Comorbid pathology research: Explore interactions between cerebrovascular complications and gut dysbiosis in AD patients.
  • Longitudinal monitoring: Launch long-term follow-up trials to map dynamic microbiome shifts alongside disease progression.
  • Multimodal integration: Combine PET/MRI neuroimaging to correlate gut microbial changes with cerebral structural and functional transformations.

Conclusion

Findings advance mechanistic understanding of preclinical AD pathogenesis. Gut microbiota is poised to become a novel early diagnostic biomarker and precision therapeutic target, opening new avenues to delay or halt AD progression.

0
0
Loading